agilon health, inc. (AGL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AGL SEC filings page.
agilon health, inc. (AGL) reported $5.9B in revenue over the twelve months to Jun 30, 2026, up 0.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a shrinking revenue base paired with wider operating losses, not operating leverage from scale.
The important shift is that FY2025 brought a lower top line while operating margin worsened from-4.8% to-7.8% ; less activity produced a larger loss per revenue dollar, pointing to weaker cost absorption rather than simple volume pressure. Operating cash flow also deepened from-$58M to-$106M while free cash flow deteriorated in the same direction, so the deterioration reached both earnings and cash.
At FY2025, the company combined a 1.0x current ratio with 0.1x debt-to-equity: reported debt is modest relative to equity, but near-parity current assets and liabilities leave less short-term flexibility than the debt figure alone suggests.
Reported liquidity equaled 32.4 months of the latest annual operating outflow, a balance-sheet comparison rather than evidence that operations funded themselves. FY2025 operating cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of agilon health, inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
agilon health, inc. has an operating margin of -7.8%, meaning the company loses $8 on every $100 of revenue. This results in a profitability score of 28/100. This is down from -4.8% the prior year.
agilon health, inc.'s revenue declined 2.1% year-over-year, from $6.1B to $5.9B. This contraction results in a growth score of 79/100.
agilon health, inc. carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.
agilon health, inc.'s current ratio of 1.02 is below the typical benchmark, resulting in a score of 19/100. This tight liquidity could limit financial flexibility if cash inflows slow.
agilon health, inc.'s operations used $105.8M of cash, and capex of $13.2M added to the outflow, for a free cash flow shortfall of $119.0M. This results in a cash flow score of 21/100.
agilon health, inc. posts a -308.8% return on equity (ROE), meaning it loses $309 for every $100 of shareholders' equity. This results in a returns score of 10/100. This is down from -55.2% the prior year.
agilon health, inc. scores 2.03, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
agilon health, inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
agilon health, inc. reported a net loss of $391.3M while operations used $105.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
agilon health, inc. reported an operating loss of $463.2M against $6.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
agilon health, inc. generated $1.5B in revenue in Q2 2026. This represents an increase of 7.2% from the same quarter a year earlier. Against the prior quarter it is up 5.2%.
agilon health, inc.'s EBITDA was $18.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 117.1% from the same quarter a year earlier. Against the prior quarter it is up 72.8%.
agilon health, inc. reported $18.0M in net income in Q2 2026. This represents an increase of 117.2% from the same quarter a year earlier. Against the prior quarter it is down 63.3%.
agilon health, inc. earned $1.04 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 64.6%.
Cash & Balance Sheet
agilon health, inc. recorded an outflow of $60.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 58.5% from the same quarter a year earlier. Against the prior quarter it is down 394.5%.
agilon health, inc. held $107.2M in cash against $15.4M in long-term debt as of Q2 2026, with $1.3B of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
agilon health, inc.'s operating margin was 0.8% in Q2 2026, reflecting core business profitability. This is up 9.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
agilon health, inc.'s net profit margin was 1.2% in Q2 2026, showing the share of revenue converted to profit. This is up 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.2 percentage points.
agilon health, inc.'s ROE was 7.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 33.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 19.1 percentage points.
Not reported for Q2 2026.
Capital Allocation
agilon health, inc. invested $3.4M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 6.1% from the same quarter a year earlier. Against the prior quarter it is up 11.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B+7.2% | $1.4B-7.3% | $1.6B+3.1% | $1.4B-1.1% | $1.4B-5.9% | $1.5B-4.5% | $1.5B+44.2% | $1.5B+27.6% |
| SG&A Expenses | $88.5M+57.3% | $54.2M-17.8% | $60.1M+0.6% | $56.2M-11.0% | $56.3M-19.2% | $66.0M-13.7% | $59.8M-7.6% | $63.1M-12.4% |
| Operating Income | $11.8M+110.1% | $4.0M+118.1% | -$193.8M-79.3% | -$131.3M+1.7% | -$116.0M-167.7% | -$22.1M-208.0% | -$108.1M+34.2% | -$133.5M-239.8% |
| EBITDA | $18.6M+117.1% | $10.8M+170.8% | -$186.9M-83.9% | -$123.8M+2.7% | -$108.7M-190.4% | -$15.2M-1042.0% | -$101.6M+35.2% | -$127.3M-261.4% |
| Interest Expense | $1.6M+2.3% | $1.8M+19.5% | $1.7M+9.0% | $1.8M+13.3% | $1.6M-7.4% | $1.5M+18.0% | $1.6M-18.3% | $1.6M-1.8% |
| Income Tax | -$375K-704.8% | $28K-85.7% | $1.3M-24.6% | -$331K+43.9% | $62K-85.1% | $196K+247.4% | $1.8M+558.1% | -$590K-148.8% |
| Net Income | $18.0M+117.2% | $48.9M+303.9% | -$188.9M-78.5% | -$110.2M+6.3% | -$104.4M-240.2% | $12.1M+299.7% | -$105.8M+54.1% | -$117.6M-274.1% |
| EPS (Basic) | $1.07+117.0% | $2.95+304.1% | -$0.46-76.9% | -$0.27+6.9% | -$6.31-8914.3% | $0.73+7200.0% | -$0.26+36.6% | -$0.29-383.3% |
| EPS (Diluted) | $1.04 | $2.94 | -$0.46-76.9% | -$0.27+6.9% | -$6.31 | $0.73+7200.0% | -$0.26+36.6% | -$0.29-383.3% |
| Diluted Shares (Avg) | 17M | 17M | N/A | 414M+0.7% | 17M | 17M-96.0% | N/A | 412M+1.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
AGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B-7.1% | $1.5B-22.1% | $1.3B-26.7% | $1.6B-23.7% | $1.7B-20.8% | $1.9B-16.6% | $1.7B-0.4% | $2.1B-8.2% |
| Current Assets | $1.4B-2.3% | $1.3B-20.0% | $1.1B-24.8% | $1.3B-26.1% | $1.5B-22.9% | $1.7B-19.0% | $1.5B-1.5% | $1.8B-7.4% |
| Cash & Equivalents | $107.2M-37.5% | $140.0M+2.2% | $173.7M-7.7% | $171.7M+15.9% | $171.4M+56.6% | $136.9M+22.6% | $188.2M+75.0% | $148.2M-12.0% |
| Short-Term Investments | $78.4M-49.6% | $91.4M-60.3% | $111.4M-47.4% | $139.2M-43.1% | $155.6M-46.6% | $230.1M-25.1% | $211.7M-44.4% | $244.8M-38.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | $0-100.0% | $24.1M0.0% | $24.1M0.0% | $24.1M0.0% | $24.1M0.0% | $24.1M-61.3% |
| Total Liabilities | $1.4B+4.6% | $1.3B-7.6% | $1.1B-9.4% | $1.3B-14.9% | $1.3B-12.3% | $1.4B-12.0% | $1.3B+17.0% | $1.5B+7.8% |
| Current Liabilities | $1.3B+5.1% | $1.3B-7.4% | $1.1B-6.6% | $1.2B-12.0% | $1.2B-10.0% | $1.4B-10.0% | $1.2B+17.9% | $1.4B+8.3% |
| Non-Current Liabilities | $51.5M-6.2% | $51.2M-11.6% | $68.1M-38.7% | $50.3M-53.2% | $54.9M-45.2% | $57.9M-42.9% | $111.0M+8.1% | $107.4M+2.1% |
| Long-Term Debt | $15.4M | $15.3M | $15.8M-54.9% | $0-100.0% | $0-100.0% | $0-100.0% | $34.9M+8.0% | $34.9M+0.3% |
| Total Equity | $227.5M-44.4% | $181.4M-63.7% | $126.7M-73.1% | $306.1M-46.8% | $408.9M-39.6% | $500.3M-27.4% | $471.0M-28.8% | $574.9M-34.1% |
| Retained Earnings | -$1.9B-13.8% | -$1.9B-22.5% | -$2.0B-24.7% | -$1.8B-20.8% | -$1.7B-23.1% | -$1.6B-18.2% | -$1.6B-19.6% | -$1.5B-35.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
AGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$57.3M-63.3% | $23.7M+174.2% | -$20.5M-225.1% | -$18.2M-135.7% | -$35.1M-87.4% | -$32.0M+33.0% | $16.4M+126.8% | -$7.7M+40.8% |
| Depreciation & Amortization | $6.9M-6.2% | $6.8M-1.3% | $7.0M+7.3% | $7.4M+19.5% | $7.3M+23.9% | $6.9M+17.7% | $6.5M+26.2% | $6.2M+52.6% |
| Stock-Based Compensation | N/A | $6.3M-62.6% | N/A | N/A | N/A | $16.7M-1.1% | N/A | $13.3M-35.7% |
| Capital Expenditures | $3.4M+6.1% | $3.1M-19.4% | $3.0M-9.1% | $3.2M-10.2% | $3.3M-1.9% | $3.8M+22.6% | $3.3M-16.9% | $3.5M-13.5% |
| Free Cash Flow | -$60.7M-58.5% | $20.6M+157.6% | -$23.5M-278.7% | -$21.3M-89.8% | -$38.3M-74.0% | -$35.8M+29.6% | $13.2M+120.2% | -$11.2M+34.3% |
| Investing Cash Flow | $19.9M-71.7% | $19.3M+183.5% | $22.6M-4.6% | $18.7M-59.9% | $70.5M+286.8% | -$23.1M-144.9% | $23.7M+1174.6% | $46.6M+522.0% |
| Financing Cash Flow | $4.6M+279.5% | -$5.1M-3096.9% | -$17K+22.7% | -$236K+83.2% | -$2.6M-50.5% | -$161K-128.8% | -$22K+97.4% | -$1.4M-199.7% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
AGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.8%+9.1pp | 0.3%+1.7pp | -12.3%-5.3pp | -9.2%+0.1pp | -8.3%-5.4pp | -1.4%-1.0pp | -7.1%+8.5pp | -9.2%-5.7pp |
| Net Margin | 1.2%+8.7pp | 3.4%+2.6pp | -12.0%-5.1pp | -7.7%+0.4pp | -7.5%-5.4pp | 0.8%+1.2pp | -7.0%+14.9pp | -8.1%-5.3pp |
| Return on Equity | 7.9%+33.4pp | 27.0%+24.5pp | -149.0%-126.6pp | -36.0%-15.5pp | -25.5%-21.0pp | 2.4%+3.3pp | -22.5%+12.4pp | -20.5%-16.9pp |
| Return on Assets | 1.1%+7.2pp | 3.3%+2.6pp | -14.9%-8.8pp | -6.9%-1.3pp | -6.1%-4.7pp | 0.6%+0.9pp | -6.1%+7.1pp | -5.6%-4.2pp |
| Current Ratio | 1.08-0.1x | 1.04-0.2x | 1.02-0.2x | 1.08-0.2x | 1.16-0.2x | 1.20-0.1x | 1.27-0.2x | 1.29-0.2x |
| Debt-to-Equity | 0.07+0.1x | 0.08+0.1x | 0.12+0.1x | 0.00-0.1x | 0.000.0x | 0.000.0x | 0.070.0x | 0.060.0x |
| Asset Turnover | 0.94+0.1x | 0.94+0.2x | 1.23+0.4x | 0.90+0.2x | 0.81+0.1x | 0.79+0.1x | 0.88+0.3x | 0.69+0.2x |
| FCF Margin | -4.1%-1.3pp | 1.5%+3.8pp | -1.5%-2.4pp | -1.5%-0.7pp | -2.8%-1.3pp | -2.3%+0.8pp | 0.9%+7.0pp | -0.8%+0.7pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| agilon health, inc. AGL | FY2025 | $5.9B | -$391.3M | -6.6% | $1.4B | 39/100 |
| Nutex Health Inc. NUTX | FY2025 | $875.3M | $70.8M | 8.1% | $1.4B | 80/100 |
| Auna S.A. AUNA | FY2025 | N/A | N/A | N/A | $377.7M | — |
| Community Health Systems, Inc. CYH | FY2025 | $12.5B | $509.0M | 4.1% | $385.0M | 39/100 |
| Enhabit, Inc. EHAB | FY2025 | $1.1B | -$4.6M | -0.4% | $706.9M | 28/100 |
| Sonida Senior Living, Inc. SNDA | FY2025 | $381.1M | -$72.5M | -19.0% | $1.7B | 47/100 |
Where agilon health, inc. Ranks
Frequently Asked Questions
What is agilon health, inc.'s annual revenue?
agilon health, inc. (AGL) reported $5.9B in total revenue for fiscal year 2025. This represents a -2.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is agilon health, inc.'s revenue growing?
agilon health, inc. (AGL) revenue declined by 2.1% year-over-year, from $6.1B to $5.9B in fiscal year 2025.
Is agilon health, inc. profitable?
No, agilon health, inc. (AGL) reported a net income of -$391.3M in fiscal year 2025, with a net profit margin of -6.6%.
What is agilon health, inc.'s EBITDA?
agilon health, inc. (AGL) had EBITDA of -$434.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does agilon health, inc. have?
As of fiscal year 2025, agilon health, inc. (AGL) had $173.7M in cash and equivalents against $15.8M in long-term debt.
What is agilon health, inc.'s operating margin?
agilon health, inc. (AGL) had an operating margin of -7.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is agilon health, inc.'s net profit margin?
agilon health, inc. (AGL) had a net profit margin of -6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is agilon health, inc.'s return on equity (ROE)?
agilon health, inc. (AGL) has a return on equity of -308.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is agilon health, inc.'s free cash flow?
agilon health, inc. (AGL) recorded an outflow of $119.0M in free cash flow during fiscal year 2025. This represents a -67.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is agilon health, inc.'s operating cash flow?
agilon health, inc. (AGL) recorded an outflow of $105.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are agilon health, inc.'s total assets?
agilon health, inc. (AGL) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are agilon health, inc.'s capital expenditures?
agilon health, inc. (AGL) invested $13.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is agilon health, inc.'s current ratio?
agilon health, inc. (AGL) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is agilon health, inc.'s debt-to-equity ratio?
agilon health, inc. (AGL) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is agilon health, inc.'s return on assets (ROA)?
agilon health, inc. (AGL) had a return on assets of -30.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is agilon health, inc.'s P/E ratio?
agilon health, inc. (AGL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is agilon health, inc.'s price-to-sales ratio?
agilon health, inc. (AGL) trades at 0.2x sales, its market capitalization divided by revenue of $5.9B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does agilon health, inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, agilon health, inc. (AGL) held $285.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $105.8M over that year. Dividing the one by the other, the reported balance equals about 32 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is agilon health, inc.'s Altman Z-Score?
agilon health, inc. (AGL) has an Altman Z-Score of 2.03, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is agilon health, inc.'s Piotroski F-Score?
agilon health, inc. (AGL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are agilon health, inc.'s earnings high quality?
agilon health, inc. (AGL) reported a net loss of $391.3M while operations used $105.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can agilon health, inc. cover its interest payments?
agilon health, inc. (AGL) reported an operating loss of $463.2M against $6.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is agilon health, inc.?
agilon health, inc. (AGL) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.